ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - bromocriptine mesilate, quantity: 5.735 mg (equivalent: bromocriptine, qty 5 mg) - capsule, hard - excipient ingredients: iron oxide red; gelatin; magnesium stearate; titanium dioxide; lactose monohydrate; shellac; indigo carmine; maleic acid; colloidal anhydrous silica; maize starch - prevention of onset of lactation in the puerperium for clearly defined medical reasons. therapy should be continued for 14 days to prevent rebound lactation. parlodel should not be used to suppress established lactation. treatment of hyperprolactinaemia where surgery and/or radiotherapy are not indicated or have already been used with incomplete resolution. precautions should be taken to ensure that the hyperprolactinaemia is not due to severe primary hypothyroidism. where the cause of hyperprolactinaemia is a prolactin-secreting microadenoma or macroadenoma, parlodel is indicated for conservative treatment; prior to surgery in order to reduce tumour size and to facilitate removal; after surgery if prolactin level is still elevated. adjunctive therapy in the management of acromegaly when: (1) the patient refuses surgery and/or radiotherapy; (2) surgery and/or radiotherapy has been unsuccessful or full effects are not expected for some months; (3) a manifestation of the acromegaly needs to be brought under con

नाइजीरिया - अंग्रेज़ी - NAFDAC (National Agency for Food and Drugs Administration and Control)

bromocriptine mesylate 2.5mg

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

glaxosmithkline consumer healthcare australia pty ltd - atropine sulfate monohydrate,hyoscine hydrobromide,hyoscyamine sulfate dihydrate,kaolin,pectin -

आयरलैंड - अंग्रेज़ी - HPRA (Health Products Regulatory Authority)

novartis pharmaceuticals uk ltd - bromocriptine mesilate - capsule - 10 milligram

भारत - अंग्रेज़ी - Central Drugs Standard Control Organization

novartis - bromocriptine - tab - 2.5 mg - 10

न्यूज़ीलैंड - अंग्रेज़ी - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - bromocriptine mesilate 11.48mg - capsule - 10 mg - active: bromocriptine mesilate 11.48mg excipient: gelatin magnesium stearate

न्यूज़ीलैंड - अंग्रेज़ी - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - bromocriptine mesilate 2.87mg equivalent to bromocriptine 2.5 mg - tablet - 2.5 mg - active: bromocriptine mesilate 2.87mg equivalent to bromocriptine 2.5 mg excipient: colloidal silicon dioxide disodium edetate dihydrate lactose monohydrate magnesium stearate maize starch maleic acid pregelatinised maize starch

न्यूज़ीलैंड - अंग्रेज़ी - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - bromocriptine 10mg - modified release capsule - 10 mg - active: bromocriptine 10mg

न्यूज़ीलैंड - अंग्रेज़ी - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - bromocriptine 2.5mg - modified release capsule - 2.5 mg - active: bromocriptine 2.5mg

न्यूज़ीलैंड - अंग्रेज़ी - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - bromocriptine 5mg - modified release capsule - 5 mg - active: bromocriptine 5mg